New research initiative is designed to treat PTSD TBI, and other neurological and psychiatric disorders.

MGH Announces Initiative to Develop Implantable Device to Treat PTSD and TBI

Initiative made possible by $30 million DARPA contract

27/May/2014

Courtesy of MGH and Draper Labs

BOSTON – Investigators at Massachusetts General Hospital (MGH) today announced a new research initiative designed to treat post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and other neurological and psychiatric disorders. The goal of the project, which is made possible by a $30 million grant from the Defense Advanced Research Projects Agency (DARPA), is to design and build a first-of-its-kind implantable deep brain stimulation (DBS) device which will monitor signals across multiple brain structures in real time. Based on the monitored activity, it will then deliver stimulation to key areas to alleviate symptoms related to neuropsychiatric disorders such as PTSD, severe depression, drug addiction, and TBI.

“Deep brain stimulation has been shown to be an effective treatment for a variety of brain diseases, especially those involving movement like Parkinson’s disease,” says Emad Eskandar MD, director of functional neurosurgery at MGH and the project’s principal investigator. “Our goal is to take DBS to the next level and create an implantable device to treat disorders like PTSD and TBI. Together with our partners we’re committed to developing this technology, which we hope will be a bold new step toward treating those suffering from these debilitating disorders.”

The initiative, called Transdiagnostic Restoration of Affective Networks by System Identification and Function Oriented Real-Modeling and Deep Brain Stimulation (TRANSFORM DBS), involves cross-hospital collaborations along with partners from the Massachusetts Institute of Technology (MIT), and Draper Labs. The MGH-based team will include the departments of Neurosurgery, Psychiatry, Neurology, Anesthesia and Critical Care, and the Martinos Center for Biomedical Imaging. The TRANSFORM DBS team will also work closely with scientists at Draper Laboratories, who will be responsible for the engineering portions of the project.

“We’re strongly encouraged by the previous data connected with this approach,” says Eskandar. “Our hope is that this project will not only restore quality of life for those affected, both military and civilian, but dramatically change the way we approach the treatment of neuropsychiatric disorders.”

About the Massachusetts General Hospital

Massachusetts General Hospital (www.massgeneral.org), founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $785 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

Media Contacts: Mike Morrison: 617-724-6425; mdmorrison@partners.org